The nuclear center has two sections. Clinical department and production area. PET-CT is currently used in the clinical part. In addition, it has its own cyclotron for the production of short-lived radiopharmaceuticals and a synthesis laboratory. The established laboratory that provides the synthesis of radiopharmaceuticals that meet all the requirements of radiation protection.
To date, our center produces more than 10 types of radiopharmaceuticals, such as 18F-FDG, 18F-NaF, 18F-FES, 18F-FDOPA, 18F-PSMA, 68Ga-DOTATATE, 68Ga-PSMA, which meets all GMP requirements. In addition to the diagnosis of various types of cancer, targeted radionuclide therapy of advanced prostate cancer and neuroendocrine tumors is performed using ligand radio stations labeled 177Lu-PSMA / DOTA and 225Ac-PSMA / DOTA.
In the clinical department of the department there are 3 doctors, 2 radiologists and 1 nurse. The production employs 6 people. Including 1 pharmacist, 2 chemists and 1 biochemist. All the employees have been well trained at the university abroad and have regularly participated in international congresses such as EANM and SNMMI.
The Center has signed a Memorandum of Cooperation between the University of Liverpool Hospital, University College London Hospital and the Medical University of Vienna in Austria and maintains close cooperation in the field of scientific research.